151 related articles for article (PubMed ID: 35226658)
21. PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.
Jin C; Hacking S; Liang S; Nasim M
Int J Surg Pathol; 2020 Feb; 28(1):31-37. PubMed ID: 31311367
[No Abstract] [Full Text] [Related]
22. PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.
Elbaek MV; Pedersen MØ; Breinholt MF; Reddy A; Love C; Clasen-Linde E; Knudsen H; Nielsen SL; Gang AO; Høgdall E; Dave S; Nørgaard P
Hematol Oncol; 2019 Oct; 37(4):375-382. PubMed ID: 31408531
[TBL] [Abstract][Full Text] [Related]
23. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
[TBL] [Abstract][Full Text] [Related]
24. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
26. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
Rowe M; Krishnan R; Mills A; Ring K
Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
[TBL] [Abstract][Full Text] [Related]
27. Loss of DNA mismatch repair proteins in prostate cancer.
Sharma M; Yang Z; Miyamoto H
Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract][Full Text] [Related]
29. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
Engerud H; Berg HF; Myrvold M; Halle MK; Bjorge L; Haldorsen IS; Hoivik EA; Trovik J; Krakstad C
Gynecol Oncol; 2020 Apr; 157(1):260-267. PubMed ID: 31973911
[TBL] [Abstract][Full Text] [Related]
30. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
Jang BS; Kim IA
Radiother Oncol; 2017 Sep; 124(3):403-410. PubMed ID: 28579282
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
32. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.
Yoo SH; Keam B; Ock CY; Kim S; Han B; Kim JW; Lee KW; Jeon YK; Jung KC; Chung EJ; Kwon SK; Ahn SH; Sung MW; Heo DS
Sci Rep; 2019 May; 9(1):7680. PubMed ID: 31118488
[TBL] [Abstract][Full Text] [Related]
34. Studies on selected molecular factors in endometrial cancers.
Markowska A; Szarszewska M; Żurawski J; Sajdak S; Knapp P; Gryboś A; Olejek A; Bednarek W; Roszak A; Jóźwik M; Marszałek A; Filas V; Wójcik-Krowiranda K; Mądry R; Markowska J; Sozański R
Adv Clin Exp Med; 2018 Oct; 27(10):1417-1424. PubMed ID: 30277666
[TBL] [Abstract][Full Text] [Related]
35. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
Kawahara T; Ishiguro Y; Ohtake S; Kato I; Ito Y; Ito H; Makiyama K; Kondo K; Miyoshi Y; Yumura Y; Hayashi N; Hasumi H; Osaka K; Muraoka K; Izumi K; Teranishi JI; Uemura H; Yao M; Nakaigawa N
BMC Urol; 2018 Nov; 18(1):97. PubMed ID: 30400941
[TBL] [Abstract][Full Text] [Related]
36. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
Zighelboim I; Goodfellow PJ; Gao F; Gibb RK; Powell MA; Rader JS; Mutch DG
J Clin Oncol; 2007 May; 25(15):2042-8. PubMed ID: 17513808
[TBL] [Abstract][Full Text] [Related]
37. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
39. NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.
Zhu SD; Zhang J; Liu XJ; Zhang JH; Wei B; Wang WY; Fan YJ; Li D; Cao YX; Zhan L
Technol Cancer Res Treat; 2022; 21():15330338221112742. PubMed ID: 35880269
[No Abstract] [Full Text] [Related]
40. Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.
Yang L; Huang F; Mei J; Wang X; Zhang Q; Wang H; Xi M; You Z
Int J Gynecol Cancer; 2017 Feb; 27(2):196-205. PubMed ID: 27870715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
